Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.

医学 无容量 耐受性 易普利姆玛 围手术期 肝细胞癌 临床终点 内科学 外科 佐剂 肿瘤科
作者
Ahmed Omar Kaseb,Elshad Hasanov,Hop Sanderson Tran Cao,Lianchun Xiao,Jean-Nicolas Vauthey,Sunyoung S Lee,Betul Gok Yavuz,Yehia I Mohamed,Aliya Qayyum,Sonali Jindal,Fei Duan,Sreyashi Basu,Shalini S Yadav,Courtney Nicholas,Jing Jing Sun,Kanwal Pratap Singh Raghav,Asif Rashid,Kristen Carter,Yun Shin Chun,Ching-Wei David Tzeng,Divya Sakamuri,Li Xu,Ryan Sun,Vittorio Cristini,Laura Beretta,James C Yao,Robert A Wolff,James Patrick Allison,Padmanee Sharma
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:7 (3): 208-218
标识
DOI:10.1016/s2468-1253(21)00427-1
摘要

Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy has been shown to improve survival in advanced hepatocellular carcinoma; we therefore aimed to evaluate the safety and tolerability of perioperative immunotherapy in resectable hepatocellular carcinoma.In this single-centre, randomised, open-label, phase 2 trial, patients with resectable hepatocellular carcinoma were randomly assigned (1:1) to receive 240 mg of nivolumab intravenously every 2 weeks (for up to three doses before surgery at 6 weeks) followed in the adjuvant phase by 480 mg of nivolumab intravenously every 4 weeks for 2 years, or 240 mg of nivolumab intravenously every 2 weeks (for up to three doses before surgery) plus one dose of 1 mg/kg of ipilimumab intravenously concurrently with the first preoperative dose of nivolumab, followed in the adjuvant phase by 480 mg of nivolumab intravenously every 4 weeks for up to 2 years plus 1 mg/kg of ipilimumab intravenously every 6 weeks for up to four cycles. Patients were randomly assigned to the treatment groups by use of block randomisation with a random block size. The primary endpoint was the safety and tolerability of nivolumab with or without ipilimumab. Secondary endpoints were the proportion of patients with an overall response, time to progression, and progression-free survival. This trial is registered with ClinicalTrials.gov (NCT03222076) and is completed.Between Oct 30, 2017, and Dec 3, 2019, 30 patients were enrolled and 27 were randomly assigned: 13 to nivolumab and 14 to nivolumab plus ipilimumab. Grade 3-4 adverse events were higher with nivolumab plus ipilimumab (six [43%] of 14 patients) than with nivolumab alone (three [23%] of 13). The most common treatment-related adverse events of any grade were increased alanine aminotransferase (three [23%] of 13 patients on nivolumab vs seven [50%] of 14 patients on nivolumab plus ipilimumab) and increased aspartate aminotransferase (three [23%] vs seven [50%]). No patients in either group had their surgery delayed due to grade 3 or worse adverse events. Seven of 27 patients had surgical cancellations, but none was due to treatment-related adverse events. Estimated median progression-free survival was 9·4 months (95% CI 1·47-not estimable [NE]) with nivolumab and 19·53 months (2·33-NE) with nivolumab plus ipilimumab (hazard ratio [HR] 0·99, 95% CI 0·31-2·54); median time to progression was 9·4 months (95% CI 1·47-NE) in the nivolumab group and 19·53 months (2·33-NE) in the nivolumab plus ipilimumab group (HR 0·89, 95% CI 0·31-2·54). In an exploratory analysis, three (23%) of 13 patients had an overall response with nivolumab monotherapy, versus none with nivolumab plus ipilimumab. Three (33%) of nine patients had a major pathological response (ie, ≥70% necrosis in the resected tumour area) with nivolumab monotherapy compared with three (27%) of 11 with nivolumab plus ipilimumab.Perioperative nivolumab alone and nivolumab plus ipilimumab appears to be safe and feasible in patients with resectable hepatocellular carcinoma. Our findings support further studies of immunotherapy in the perioperative setting in hepatocellular carcinoma.Bristol Myers Squibb and the US National Institutes of Health.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
香香关注了科研通微信公众号
2秒前
NightGlow完成签到,获得积分10
2秒前
3秒前
安静无招完成签到 ,获得积分10
4秒前
4秒前
NexusExplorer应助fengliurencai采纳,获得10
6秒前
NexusExplorer应助古月采纳,获得10
6秒前
星辰大海应助33采纳,获得10
8秒前
彭彭发布了新的文献求助10
10秒前
12秒前
老大蒂亚戈应助潇湘雪月采纳,获得10
13秒前
13秒前
15秒前
15秒前
kk完成签到,获得积分10
15秒前
16秒前
HOPE发布了新的文献求助10
16秒前
AAA完成签到,获得积分10
18秒前
Singularity应助讨厌科研采纳,获得10
18秒前
古月发布了新的文献求助10
19秒前
20秒前
33发布了新的文献求助10
20秒前
汉堡包应助于平川春野采纳,获得10
20秒前
星星发布了新的文献求助10
22秒前
23秒前
赘婿应助十九岁的时差采纳,获得10
23秒前
怠惰vs勤劳完成签到,获得积分10
24秒前
夏天应助青山采纳,获得100
25秒前
26秒前
乖猫要努力应助潇湘雪月采纳,获得10
27秒前
wdy111举报风之星求助涉嫌违规
27秒前
古月完成签到,获得积分10
28秒前
28秒前
29秒前
吴所谓发布了新的文献求助50
32秒前
英吉利25发布了新的文献求助10
33秒前
34秒前
酷波er应助南冥采纳,获得10
34秒前
李沐唅完成签到 ,获得积分10
38秒前
lv完成签到,获得积分10
38秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989390
求助须知:如何正确求助?哪些是违规求助? 3531487
关于积分的说明 11254109
捐赠科研通 3270153
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809174